Pharmacokinetics and pharmacodynamics of erythropoietin receptor in healthy volunteers

被引:0
|
作者
Wojciech Krzyzanski
Elzbieta Wyska
机构
[1] University at Buffalo,Department of Pharmaceutical Sciences
[2] State University of New York,Department of Pharmacokinetics and Physical Pharmacy
[3] Jagiellonian University,undefined
来源
Naunyn-Schmiedeberg's Archives of Pharmacology | 2008年 / 377卷
关键词
Target-mediated drug disposition; Pharmacokinetic model; Receptor binding; Internalization;
D O I
暂无
中图分类号
学科分类号
摘要
The purpose of this study was to apply the target-mediated drug disposition (TMDD) pharmacokinetic (PK) model to describe binding, internalization, and turnover of erythropoietin receptor (EPOR). This model allows one to determine from free drug (C) PK data not only parameters describing linear disposition of EPO such as the elimination rate constant (kel) and volume of distribution (Vc), but also the total receptor concentration (Rtot0), drug–receptor complex (RC) internalization rate constant (kint), as well as synthesis and degradation rate constants (ksyn and kdeg) for the receptor turnover. The previously published data on PK of recombinant EPO (rHuEPO) in humans and the results of EPOR binding studies were used for analysis. The estimated PK parameters were used to simulate time courses of free and bound EPOR after IV administration of clinically relevant rHuEPO doses. The estimates of kel = 0.106 h−1 and Vc = 0.032 l/kg are consistent with reported in the literature values of rHuEPO linear disposition parameters. The determined value of Rtot0 was 66.35 pM and the half-life for EPOR degradation was 8.8 h. Computer simulations showed a very rapid binding phase in the EPOR time profile followed by a decline to a nadir, and a subsequent return to the baseline. The nadir values decreased with increasing doses and resulted in the maximum values of the bound fractions of the total EPOR in the ranges 33–99%. At the baseline conditions, only 3.1% of EPOR were occupied. The saturation of EPOR was correlated with the time C remained above the KD level. In conclusion, the time courses of serum rHuEPO concentrations contain information about internalization and turnover of EPOR. Kinetics of EPOR can be utilized to determine the relationship between the pharmacologic effect and exposure to rHuEPO.
引用
收藏
页码:637 / 645
页数:8
相关论文
共 50 条
  • [31] Pharmacokinetics, pharmacodynamics, and safety assessment of palifermin (rHuKGF) in healthy volunteers
    Zia-Amirhosseini, Parnian
    Salfi, Margaret
    Leese, Philip
    Yates, Wayne
    Danilenko, Dimitry M.
    Ring, Brian
    Cesano, Alessandra
    Sullivan, John T.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 79 (06) : 558 - 569
  • [32] Population pharmacokinetics and pharmacodynamics of bivalirudin in young healthy Chinese volunteers
    Dong-mei Zhang
    Kun Wang
    Xia Zhao
    Yun-fei Li
    Qing-shan Zheng
    Zi-ning Wang
    Yi-min Cui
    Acta Pharmacologica Sinica, 2012, 33 : 1387 - 1394
  • [33] PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY OF INTRAVENOUS GANAXOLONE IN HEALTHY ADULT VOLUNTEERS
    Barra, Megan
    Vaitkevicius, Henrikas
    Husain, Aatif
    Raja, Shruti
    Macleod, David
    Guptill, Jeff
    Gasior, Maciej
    Rybak, Eva
    CRITICAL CARE MEDICINE, 2023, 51 (01) : 398 - 398
  • [34] THE INFLUENCE OF ORLISTAT ON THE PHARMACOKINETICS AND PHARMACODYNAMICS OF GLYBURIDE IN HEALTHY-VOLUNTEERS
    ZHI, J
    MELIA, AT
    KOSSTWARDY, SG
    MIN, B
    GUERCIOLINI, R
    FREUNDLICH, NL
    MILLA, G
    PATEL, IH
    JOURNAL OF CLINICAL PHARMACOLOGY, 1995, 35 (05): : 521 - 525
  • [35] PRELIMINARY STUDIES OF THE PHARMACOKINETICS AND PHARMACODYNAMICS OF PROCHLORPERAZINE IN HEALTHY-VOLUNTEERS
    TAYLOR, WB
    BATEMAN, DN
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1987, 23 (02) : 137 - 142
  • [36] Pharmacokinetics and pharmacodynamics of IFN-β1a in healthy volunteers
    Buchwalder, PA
    Buclin, T
    Trinchard, I
    Munafo, A
    Biollaz, J
    JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 2000, 20 (10): : 857 - 866
  • [37] Effects of Danshen capsules on the pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers
    Zhou, Chun-hua
    Xu, Meng
    Yu, Hai-bing
    Zheng, Xiao-ting
    Zhong, Zhang-feng
    Zhang, Lan-tong
    FOOD AND CHEMICAL TOXICOLOGY, 2018, 119 : 302 - 308
  • [38] Pharmacokinetics and pharmacodynamics of a new intranasal midazolam formulation in healthy volunteers
    Wermeling, Daniel P.
    Record, Kenneth A.
    Kelly, Thomas H.
    Archer, Sanford M.
    Clinch, Thomas
    Rudy, Anita C.
    ANESTHESIA AND ANALGESIA, 2006, 103 (02): : 344 - 349
  • [39] EFFECT OF POLYMORPHISMS ON THE PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY OF RISPERIDONE IN HEALTHY VOLUNTEERS
    Cabaleiro, T.
    Ochoa, D.
    Lopez-Rodriguez, R.
    Roman, M.
    Ayuso, C.
    Abad-Santos, F.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2014, 115 : 52 - 52
  • [40] PHARMACOKINETICS AND PHARMACODYNAMICS OF MIGALASTAT, A PHARMACOLOGICAL CHAPERONE OF α GALACTOSIDASE A, IN HEALTHY VOLUNTEERS
    Greene, D.
    Bragat, A.
    Adera, M.
    Boudes, P.
    JOURNAL OF INHERITED METABOLIC DISEASE, 2011, 34 : S190 - S190